2.50
Hdl Handle:
http://hdl.handle.net/10541/76355
Title:
Treatment of pituitary tumors: pegvisomant.
Authors:
Paisley, Angela N; Drake, William M
Abstract:
Pegvisomant is a pegylated analog of growth that functions as a growth hormone receptor antagonist. The drug is capable of normalizing serum IGF-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients, and therapy is associated with significant improvements in the symptoms and signs of GH excess. Biochemical control may be achieved with pegvisomant in patients wholly or partially resistant to somatostatin analogs, and there are emerging data to suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, England.
Citation:
Treatment of pituitary tumors: pegvisomant. 2005, 28 (1):111-4 Endocrine
Journal:
Endocrine
Issue Date:
Oct-2005
URI:
http://hdl.handle.net/10541/76355
DOI:
10.1385/ENDO:28:1:111
PubMed ID:
16311417
Type:
Article
Language:
en
ISSN:
0969-711X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaisley, Angela N-
dc.contributor.authorDrake, William M-
dc.date.accessioned2009-08-05T12:28:58Z-
dc.date.available2009-08-05T12:28:58Z-
dc.date.issued2005-10-
dc.identifier.citationTreatment of pituitary tumors: pegvisomant. 2005, 28 (1):111-4 Endocrineen
dc.identifier.issn0969-711X-
dc.identifier.pmid16311417-
dc.identifier.doi10.1385/ENDO:28:1:111-
dc.identifier.urihttp://hdl.handle.net/10541/76355-
dc.description.abstractPegvisomant is a pegylated analog of growth that functions as a growth hormone receptor antagonist. The drug is capable of normalizing serum IGF-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients, and therapy is associated with significant improvements in the symptoms and signs of GH excess. Biochemical control may be achieved with pegvisomant in patients wholly or partially resistant to somatostatin analogs, and there are emerging data to suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.en
dc.language.isoenen
dc.subjectPituitary Canceren
dc.subject.meshAdenoma-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshPituitary Neoplasms-
dc.subject.meshReceptors, Somatotropin-
dc.titleTreatment of pituitary tumors: pegvisomant.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, England.en
dc.identifier.journalEndocrineen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.